39,845 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Acquired by Centiva Capital LP

Centiva Capital LP bought a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 39,845 shares of the company’s stock, valued at approximately $324,000. Centiva Capital LP owned 0.07% of Health Catalyst at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Light Asset Management LLC grew its stake in Health Catalyst by 438.5% in the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Impax Asset Management Group plc grew its stake in Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock worth $20,793,000 after buying an additional 360,201 shares in the last quarter. Millennium Management LLC grew its stake in Health Catalyst by 96.3% in the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA grew its stake in Health Catalyst by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock worth $19,572,000 after buying an additional 25,000 shares in the last quarter. Finally, Daventry Group LP grew its stake in Health Catalyst by 3.9% in the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock worth $14,359,000 after buying an additional 84,178 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Trading Up 0.4 %

NASDAQ:HCAT opened at $8.37 on Wednesday. The company has a fifty day moving average of $8.13 and a 200 day moving average of $7.39. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $509.30 million, a P/E ratio of -6.20 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the company earned ($0.22) earnings per share. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, research analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Ratings Changes

HCAT has been the subject of a number of research reports. Evercore ISI boosted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. upped their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th. Citigroup upped their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Royal Bank of Canada upped their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research note on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.79.

Insiders Place Their Bets

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $7.68, for a total value of $40,005.12. Following the completion of the transaction, the chief operating officer now directly owns 134,899 shares in the company, valued at approximately $1,036,024.32. This represents a 3.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Jason Alger sold 19,599 shares of the stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the transaction, the chief financial officer now owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. The trade was a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,433 shares of company stock worth $492,503. 2.50% of the stock is currently owned by corporate insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.